Watson Pharmaceuticals has received final approval from the FDA on its abbreviated new drug application for bupropion hydrochloride extended-release tablets, 300mg.
Subscribe to our email newsletter
Bupropion hydrochloride extended-release is the generic equivalent to GlaxoSmithKline’s Wellbutrin XL tablets, which is indicated for the treatment of major depressive disorder. The company intends to launch the product immediately.